Cetuximab ± Irinotecan for Resistant KRAS, NRAS, BRAF, and PIK3CA Wild-Type Metastatic Colorectal Cancer
This phase II randomized study compared cetuximab monotherapy with irinotecan plus cetuximab among patients with resistant KRAS/ NRAS/ BRAF/ PIK3CA wild-type metastatic colorectal cancer. Patients were enrolled in an open-label, multicenter, phase II trial and randomly assigned to cetuximab 400 mg/m2, then 250 mg/m2 cetuximab weekly, with or without irinotecan 180 mg/m2 every 2 weeks. The […]
